Aurobindo Pharma has announced that the United States Food and Drug Administration (US FDA) has classified the inspection of Eugia Unit-III, a formulation manufacturing facility operated by its wholly owned subsidiary, Eugia Pharma Specialities, as Official Action Indicated (OAI).

The manufacturing facility, located in Phase 3, Telangana, was inspected by the US FDA from January 27 to February 6, 2026. At the conclusion of the inspection, the regulatory agency issued 11 observations.

In a regulatory filing, the company stated that it has now been informed of the FDA’s decision to classify the inspection outcome as OAI. An OAI classification generally indicates that the agency has identified objectionable conditions or practices during an inspection that may warrant regulatory or administrative action.

Eugia Unit 3 is involved in formulation manufacturing and forms part of Aurobindo Pharma’s broader pharmaceutical manufacturing network serving global markets.

The company reiterated its commitment to maintaining high manufacturing and quality standards across its facilities worldwide. Aurobindo Pharma stated that it remains focused on ensuring compliance with global regulatory requirements and upholding quality systems across its operations.

The OAI classification comes amid heightened regulatory scrutiny of pharmaceutical manufacturing facilities supplying medicines to international markets, particularly the United States, which remains one of the largest export destinations for Indian drug manufacturers.

Aurobindo Pharma, through its subsidiaries, operates a diversified portfolio of manufacturing facilities across various therapeutic segments and continues to emphasize quality compliance as a key component of its global operations.